Biotech continued to outperform the broader markets, with the BioCentury 100 Index up 7% and the NASDAQ Biotechnology Index up 10% in 3Q12 versus a 6% rise in the S&P 500. Excluding partnership monies, the industry raised (mostly from debt and follow-on offerings) $13 billion last quarter—the fourth highest of any quarter since 2000. Only four companies completed initial public offerings (IPOs). About $1.8 billion was raised by private biotechs, up from $1.4 billion in 2Q12 and $1.4 billion a year ago.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. Q312: Biotech on a roll. Nat Biotechnol 30, 1165 (2012). https://doi.org/10.1038/nbt.2457
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2457
